Iridex ophthalmic laser system for glaucoma treatment receives FDA approval
Iridex (NASDAQ:IRIX) has received FDA clearance to market its Cyclo G6 laser system designed solely for use in treating glaucoma and its symptoms.
Iridex (NASDAQ:IRIX; Mountain View, CA) has received FDA clearance to market its Cyclo G6 laser system designed solely for use in treating glaucoma and its symptoms. The system is dedicated specifically to treat patients diagnosed with a range of glaucoma disease states, and features the company's proprietary MicroPulse tissue-sparing technology and a family of single-use probes that connect to a laser console.
Related: Iridex laser delivery system cleared for noninvasive treatment of retinal diseases
"MicroPulse allows for a clinically effective and repeatable option that can slow the progression of the disease and delay both surgical intervention and ultimate blindness," states glaucoma and cataract specialist Robert Noecker, MD, of the Ophthalmic Consultants of Connecticut (Fairfield, CT).
The Cyclo G6 Laser System will initially be sold with two disposable delivery probes, the MicroPulse P3 probe and the G-Probe, and the company plans a series of additional new probe introductions in the coming year that allow for a broader range of application in glaucoma treatment.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!